<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273233</url>
  </required_header>
  <id_info>
    <org_study_id>EV71-1001-Ia</org_study_id>
    <nct_id>NCT01273233</nct_id>
  </id_info>
  <brief_title>Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults</brief_title>
  <official_title>A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type
      71 Vaccines in healthy adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they
      will be randomized to receive two different dosage of vaccine candidate or placebo to
      evaluate the safety of this vaccine in adults
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Infection; Viral, Enterovirus</condition>
  <arm_group>
    <arm_group_label>Group 1: 200U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 adults received 3 doses of 200U EV71 vaccine 14 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 400U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 adults received 3 doses of 400U EV71 vaccine 14 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 adults received 3 doses of placebo 14 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 adults received 3 doses of placebo 14 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Enterovirus Type 71 Vaccine</intervention_name>
    <description>A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)</description>
    <arm_group_label>Group 1: 200U EV71 vaccine</arm_group_label>
    <arm_group_label>Group 2: 400U EV71 vaccine</arm_group_label>
    <other_name>EV71 Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <other_name>EV71 Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females, aged from 18 to 49 years old. Health is determined by
             medical history, physical examination, laboratory examination and clinical judgment of
             the investigator

          2. Provided legal identification for the sake of recruitment.

          3. Subjects are able to understand and sign informed consents.

        Exclusion Criteria:

          1. Histroy of Hand-foot-mouth Disease

          2. Women of lactation, pregnancy or about to be pregnant in 60 days

          3. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine

          4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          5. Congenital malformations or developmental disorders, genetic defects, or severe
             malnutrition

          6. Epilepsy, seizures or convulsions history, or family history of mental illness

          7. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have
             autoimmune diseases or immunodeficiency

          8. History of asthma, angioedema, diabetes or malignancy

          9. History of thyroidectomy or thyroid disease that required medication within the past
             12 months

         10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

         11. Asplenia, functional asplenia or any condition resulting in the absence or removal the
             spleen

         12. Acute illness or acute exacerbation of chronic disease within the past 7 days

         13. Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

         14. History of any blood products within 3 months

         15. Administration of any live attenuated vaccine within 28 days

         16. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or
             allergy treatment within 14 days

         17. Axillary temperature &gt; 37.0 centigrade before vaccination

         18. Abnormal laboratory parameters before vaccination

         19. Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-ping Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

